Science is a game won with time and patience, through trials where errors far outweigh success. In the race against deadly diseases – COVID-19 among them – time is, of course, of the essence. And high-tech – specifically, high-tech platforms employing machine learning (ML) and artificial intelligence...
After what feels like a never-ending stream of bad news about the COVID-19 pandemic, a bit of good news started to trickle into the market last week with an announcement by Pfizer that it had achieved a better than 90 percent success rate with minimal...
Despite recent positive progress that a COVID vaccine is moving closer to becoming a reality, when it comes to the resumption of the activities, sports and shows that constitute “normal life,” event planners say they still lack the visibility and confidence to safely stage large,...
With COVID-19’s worldwide case count officially exceeding 11 million and waves of closures sweeping U.S. states in an attempt to stifle the resurgent threat, an island of good news has appeared in what looks increasingly like a sea of bad tidings. Following Pfizer’s announcement last...
On the same day that COVID-19 cases in the U.S. topped 10 million and hit 50.5 million globally, the world got news that Pfizer and BioNTech had successfully completed Phase 3 trials of a COVID-19 vaccine on 43,000 people — and achieved an astounding 90...
Ticketmaster, which handles off-site ticket sales for a huge portion of the country’s music and sports events, is developing a system to assess fans’ Covid-19 vaccination and testing status but will let local promoters set standards for attendance, the San Francisco Chronicle reported. Get the...
The highest danger from COVID-19 comes from the reopening of restaurants, gyms and hotels, according to a study using mobile phone data from 98 million people as a model for infection risk, Bloomberg reported. Get the Full Story Complete the form to unlock this article...
A new U.S. federal COVID-19 stimulus is possible, and maybe even likely, but how much – and who will get it – is less clear. Get the Full Story Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content...
Consumer confidence got a big lift on Monday (Nov. 9) on news that Pfizer and BioNTech’s ongoing COVID-19 vaccine trial has proven 90 percent effective in fighting the virus. As PYMNTS research’ has found since March, this development will be a major factor in consumers...
